Publicaciones en las que colabora con María Esteve Pardo (27)

2023

  1. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10

2022

  1. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 3, pp. 165-176

  2. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  3. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953

2021

  1. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

    Journal of Crohn's and Colitis, Vol. 15, Núm. 11, pp. 1846-1851

  2. Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience

    United European Gastroenterology Journal, Vol. 9, Núm. 7, pp. 766-772

2020

  1. COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020)

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 7, pp. 408-413

  2. Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial

    The American journal of gastroenterology, Vol. 115, Núm. 11, pp. 1802-1811

  3. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 2, pp. 97-105

  4. The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: Design, monitoring and functions

    Gastroenterologia y Hepatologia

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

    Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428

  3. EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain

    Therapeutic Advances in Gastroenterology, Vol. 12

  4. Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn’s disease

    Pharmacogenomics Journal, Vol. 19, Núm. 6, pp. 547-555

2018

  1. Addition of granulocyte/monocyte apheresis to oral prednisone for steroid-dependent ulcerative colitis: A Randomized multicentre clinical trial

    Journal of Crohn's and Colitis, Vol. 12, Núm. 6, pp. 687-694

2017

  1. Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

    American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131

2016

  1. Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project

    Inflammatory Bowel Diseases, Vol. 22, Núm. 3, pp. 583-589

  2. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. Identification of risk loci for crohn's disease phenotypes using a genome-wide association study

    Gastroenterology, Vol. 148, Núm. 4, pp. 794-805

2014

  1. A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis

    Human molecular genetics, Vol. 23, Núm. 25, pp. 6927-6934